^
Association details:
| Biomarker: | LRP1B mutation + TMB-H |
|---|---|
| Cancer: | Bladder Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
356 - Association of LRP1B mutation with tumor mutation burden and survival in bladder cancer patients treated with immune checkpoint inhibitors
Published date:
03/10/2021
Excerpt:
The association between LRP1B mutation with TMB was analyzed in bladder cancer patients from the public immunotherapy-treated cohort...LRP1B mutation is associated with higher TMB in both public cohort(p=0.028)...Survival analysis in the public cohort demonstrated that LRP1B mutation resulted in significantly longer OS ( 16.8 vs 8.08 months; HR, 0.16; p=0.043) and a increasing trend on PFS without significant difference...
